profit from every $100 of sales.
$0$100
Moderna
$223.37-3.45% today
+794.9% in 1 year
1-year low $22.361-year high $269.00
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Moderna sold, what it kept, and what it did with the cash.
Sales went from $18.9 billion in 2022 to $1.92 billion in 2025, with -$2.82 billion of profit last year.
SalesProfit
Moderna vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Moderna | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 CSL | 22.0× · Fair price | ||
 BeOne Medicines | 217.4× · Very expensive |
Compare Moderna with AbbVie · Johnson & Johnson · Eli Lilly · Merck & · Roche · UnitedHealth
AI analysis
An AI analyst reads Moderna's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 803 | 18,471 | 18,875 | 6,754 | 3,199 | 1,922 | |
| 795 | 15,854 | 13,459 | 2,061 | 1,735 | 1,054 | |
| -763 | 13,296 | 9,420 | -4,239 | -3,945 | -3,074 | |
| – | – | 9,768 | -3,618 | -3,394 | -2,543 | |
| -747 | 12,202 | 8,362 | -4,714 | -3,561 | -2,822 | |
| -1.96 | 28.29 | 20.12 | -12.33 | -9.28 | -7.26 | |
| 99.0% | 85.8% | 71.3% | 30.5% | 54.2% | 54.8% | |
| -95.0% | 72.0% | 49.9% | -62.8% | -123.3% | -159.9% | |
| -93.0% | 66.1% | 44.3% | -69.8% | -111.3% | -146.8% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 7,337 | 24,669 | 25,858 | 18,426 | 14,142 | 12,338 |
| Cash | 2,624 | 6,848 | 3,205 | 2,907 | 1,927 | 2,595 |
| Total debt | – | – | 1,200 | 1,243 | 747 | 1,305 |
| Total liabilities | 4,776 | 10,524 | 6,735 | 4,572 | 3,241 | 3,688 |
| 2,561 | 14,145 | 19,123 | 13,854 | 10,901 | 8,650 | |
| 381 | 431 | 416 | 382 | 384 | 389 | |
| – | – | 36.6% | -22.2% | -24.3% | -21.9% | |
| -29.2% | 86.3% | 43.7% | -34.0% | -32.7% | -32.6% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 2,027 | 13,620 | 4,981 | -3,118 | -3,004 | -1,873 | |
| 68 | 284 | 400 | 707 | 1,051 | 202 | |
| 1,959 | 13,336 | 4,581 | -3,825 | -4,055 | -2,075 | |
| Dividends paid | – | – | – | – | – | – |
| 0 | 857 | 3,329 | 1,153 | 0 | 2 | |
| 93 | 142 | 226 | 305 | 429 | 483 |
Valuation
- –
- –
- –
- 11.7×
- 47.0×
- –
- –
- -2.3%
- -3.1%
- 0.0%
Profitability
- 54.8%
- -159.9%
- -146.8%
- -132.9%
- -22.4%
- -8.1%
- -36.7%
- -27.8%
- -37.5%
- 131.5%
Growth
- +19.1%
- –
- +49.1%
- –
- −2.2%
Financial health
- -0.5×
- 0.15
- 11.3%
- -275.8×
- 3.29
- 2.35
- 0.19
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 17%of 952
Bottom 1%of 884
Top 29%of 886
Bottom 28%of 987
What analysts expect
- Average price target
- $39.00
- Range
- $17.00 – $63.00
- 10 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 1, 2026 | -1.18 | -3.02 | +60.9% |
| Feb 13, 2026 | -2.11 | -2.54 | +16.9% |
| Nov 6, 2025 | -0.51 | -1.87 | +72.7% |
| Aug 1, 2025 | -2.13 | -2.99 | +28.8% |
| May 1, 2025 | -2.52 | -2.92 | +13.7% |
| Feb 14, 2025 | -2.50 | -2.68 | +6.7% |
| Nov 7, 2024 | 0.03 | -1.91 | +101.6% |
| Aug 1, 2024 | -3.33 | -3.35 | +0.6% |
News
Moderna's Q3 Numbers May Have Seemed Impressive, but They Aren't Enough to Make the Stock a BuyYahoo Finance · Nov 9, 2026Notable healthcare headlines for the week: Moderna, Pfizer, and CVS Health in focusSeeking Alpha · Nov 8, 2026Stock Market Today: Nasdaq Bounces After Jobs Report; Moderna Races Higher (Live Coverage)Yahoo Finance · Nov 6, 2026Moderna raises its revenue outlook — but all eyes are on what happens next with its experimental cancer vaccineMarketWatch · Nov 6, 2026If Moderna's CEO Is Right, the Stock's Rally Could Just Be Getting StartedYahoo Finance · Nov 2, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
43No pass
Benjamin Graham
39No pass
Philip Fisher
53No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
41No pass
Terry Smith
39No pass
Questions about Moderna
Is Moderna a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Moderna AI analysis
What does Moderna do?
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. It is in Biotechnology, based in Cambridge, MA, United States, with 4,700 employees.
Does Moderna pay a dividend?
No. Moderna does not pay a dividend at the moment; in 2025 it returned $2.00 million to shareholders by buying back its own shares.
Is Moderna stock halal?
No. Moderna does not pass our halal screen: interest on its cash and securities is about 16% of its revenue. How we check
How has Moderna stock done over the past year?
Up 794.9% over the past twelve months, to $223.37. It traded between $22.36 and $269.00 and is 17.0% below its high.
Who are Moderna's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, CSL and BeOne Medicines. The peers table on this page compares their profit, growth and price with Moderna's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.